Mercodia announces the appointment of Helena Åsbrink as interim Chief Executive Officer, effective 2 November 2026.
With more than 20 years of international leadership experience in life science, Åsbrink brings extensive expertise in operational leadership, business development and leading science-driven organisations.
Åsbrink has held several senior leadership positions in the life science industry, including VP Global Operations, Immunodiagnostics at Thermo Fisher Scientific and Site Director at Galderma’s Uppsala site. Most recently, Åsbrink held a role with Nordic responsibility for laboratory medicine and pathology at Unilabs.
“The opportunity to lead Mercodia brings together my commitment to improving human health and my experience of developing businesses with a strong scientific foundation.
I am particularly inspired by the expertise within the team and look forward to working together to build on Mercodia’s established capabilities,” says Helena Åsbrink, interim CEO of Mercodia.
As interim CEO, Åsbrink will focus on building on Mercodia’s scientific and technical strengths, deepening customer partnerships and supporting the company’s continued development.
We are pleased to welcome Helena to Mercodia and look forward to working together as the company enters its next chapter.
